Truist Financial
BMY.RT

Truist Financial’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Truist Financial’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-512,240
Closed -$354K – 2787
2020
Q4 		$354K Sell
512,240
-6,559
-1% -$14K ﹤0.01% 2054
2020
Q3 		$1.17M Sell
518,799
-112,445
-18% -$321K ﹤0.01% 1303
2020
Q2 		$2.26M Sell
631,244
-76,996
-11% -$278K 0.01% 980
2020
Q1 		$2.69M Sell
708,240
-8,377
-1% -$27.6K 0.01% 863
2019
Q4 		$2.16M Buy
+716,617
New +$1.86M ﹤0.01% 1103

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Truist Financial's BMY.RT Position: Q1 2021 in Review

Truist Financial sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 512,240 shares — an estimated $354K sold.

Truist Financial first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $2.69M in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Truist Financial reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Truist Financial sold 512,240 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $354K.
  • Truist Financial first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Truist Financial's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $2.69M in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Truist Financial's 13F filing for Q1 2021, filed 17 May 2021.